The case for & against
Bull & Bear analysis
Bearish
Alaunos Therapeutics (NASDAQ: TCRT) is a preclinical-stage biopharmaceutical company specializing in the development of T-cell receptor (TCR) therapies targeting solid tumors, particularly those driven by high-frequency driver mutations such as KRAS and TP53. Positioned within the rapidly evolving oncology landscape, the firm is leveraging its proprietary technology platform, the Hunter platform, in collaboration with renowned institutions like MD Anderson Cancer Center to enhance therapeutic outcomes.
Bull says
- ↑First patient dosed in Phase I-II TCRT library trial.
- ↑Operating cash burn cut to $6.1M in Q3 2022 from $15.1M year-ago.
- ↑Cash and equivalents totaled $37.4M as of March 31, 2023.
- ↑Proprietary Sleeping Beauty technology boosts manufacturing edge over peers.
- ↑Growing clinician interest underpins anticipated robust patient enrollment.
- ↑High growth and quality factor profiles support stock resilience.
Bear says
- ↓Q1 2023 net loss hit ~$10M versus $9.8M in Q1 2022.
- ↓Q1 cash burn rose to $9.4M from $7.8M year-over-year.
- ↓CEO projects $35–40M operating outflows in 2023, heightening funding risk.
- ↓Regulatory delays in IND filings could push back trial timelines.
- ↓Weak profitability factors and elevated leverage risk signal potential distress.
- ↓Institutional skepticism and bearish technical indicators reflect investor caution.
Earnings Call · Q1 2022 · Mgmt. Guidance
Updated 07-04-2026neutral
Transcript signals
Bull points
- we recently announced the successful dosing of the first patient in our Phase I-II TCRT library trial.
- The patient has non-small cell lung cancer, and has now cleared the 28-day safety window.
- With the Bayesian trial design, it is possible that the second patient in the study will be dosed at the second dose level.
Bear points
- we have reduced our expected operating cash flow for 2022 to between $40 and $45 million,
- we have reduced our expected operating cash flow for 2022 to between $40 and $45 million,
- As we find more and more TCRs, there may be a plateau to what is biologically there, but we're nowhere near close to that right now.
Read full transcript analysis ›